DemeRx Overview

  • Founded

  • 2010

Founded
  • Status

  • Private

  • Employees

  • 4

Employees
  • Latest Deal Type

  • PE Growth

  • Financing Rounds

  • 3

  • Investments

  • 1

DemeRx General Information

Description

Operator of a clinical-stage pharmaceutical development company based in Miami, Florida. The company develops methods of treating patients for pain by administering Noribogaine, which is a non-addictive medication.

Contact Information

Website
www.demerx.com
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
  • 1951 NorthWest 7th Avenue
  • Suite 600
  • Miami, FL 33136
  • United States
+1 (786) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DemeRx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore DemeRx‘s full profile, request access.

Request a free trial

DemeRx Patents

  • 236

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 29

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

DemeRx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3147434-A1 Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids Pending 15-Jul-2019 000000000
GB-2600657-A Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids Pending 15-Jul-2019 000000000 0
GB-202201921-D0 Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids Pending 15-Jul-2019 000000000
GB-202300868-D0 Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids Pending 15-Jul-2019 000000000
US-20220265675-A1 Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids Pending 15-Jul-2019 A61K31/55
To view DemeRx’s complete patent history, request access »

DemeRx Executive Team (7)

Name Title Board Seat Contact Info
Deborah Mash Ph.D Co- Founder, Chief Executive Officer, President & Director
John Thomas Jr. Treasurer Chief Financial Officer and Secretary
Michael Karukin Ph.D Chief Operating Officer
Pascal Goldschmidt MD Chief Medical Officer, Lead Consultant Cardiology & Director
Richard Serbin Chairman
You’re viewing 5 of 7 executive team members. Get the full list »

DemeRx Board Members (12)

Name Representing Role Since
00000000000 000000 Self Board Member 000 0000
000 000000 Bolton Equities Board Member 000 0000
0000 0000000 DemeRx Board Member 000 0000
0000000 000000000- DemeRx Board Member 000 0000
0000000 000000 DemeRx Chairman 000 0000
You’re viewing 5 of 12 board members. Get the full list »

DemeRx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DemeRx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore DemeRx‘s full profile, request access.

Request a free trial

DemeRx Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 24-Jan-2020 00000 0000 Drug Discovery 0000000 0
To view DemeRx’s complete investments history, request access »